MarketBeat
07 Nov 2026, 09:21 UTC · 1h ago
What Evolent Health (EVH) Said on Its Q3 Earnings Call
Impact · against what's priced in
Evolent Health shows positive momentum through an increased 2026 EBITDA floor and a higher projected Q4 sequential step-up. While AI investments in 2027 will increase capital spending, the immediate focus is on improved medical expense ratios and expanded payer relationships.
- EVH+0.50
No priced-in read yet
- In context
The company raised its 2026 adjusted EBITDA guidance floor to $130 million from $120 million and increased its expected Q4 EBITDA step-up to $11M-$16M over Q3. Additionally, the medical expense ratio improved to 93% in Q3.
Read from the article alone
